Effectiveness of Matoride in Attention deficit - Hyperactivity disorder

Survey on short-acting methylphenidate (Ritalin) vs. long-acting methylphenidate (Matoride) effectiveness on Attention deficit Hyperactivity Disorder symptom among 6 - 18 year-old children

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181113041638N1

Enrollment

Registered

2019-02-19

Start date

2019-02-20

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit - Hyperactivity disorder. Attention-deficit hyperactivity disorder, unspecified type

Interventions

Intervention 1: Intervention group: A group in which patients will receive 10 mg per day of Ritalin Manufactured by NOVARTIS every morning before the school for ten days. Intervention 2: Intervention

Eligibility

Sex/Gender

All

Age

6 Years to 18 Years

Inclusion criteria

Inclusion criteria: Confirm the diagnosis of ADHD based on DSM-5 by pediatric psychiatrist Abscence of other major psychiatric disorder Being at least the age of 6 and maximum age of 18 years old Satisfaction of the inclusion by the parent or guardian of the patient

Exclusion criteria

Exclusion criteria: The lack of cooperation of the patient and family in order to make the full intervention Receive other drugs, except Matoride and Ritalin A medical condition that prevents use of the drugs Severe hypersensitivity to the drug

Design outcomes

Primary

Measure	Time frame
The child's performance. Timepoint: every day after school will be evaluate. Method of measurement: Parents' Conners' questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Javad Tarahi

Esfahan University of Medical Sciences

tarrahi_mj@yahoo.com+98 31 3792 3071

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026